Literature DB >> 9191781

Th1 epitope repertoire on the alpha subunit of human muscle acetylcholine receptor in myasthenia gravis.

Z Y Wang1, D K Okita, J Howard, B M Conti-Fine.   

Abstract

In myasthenia gravis (MG), CD4+ T helper cells recognize the muscle acetylcholine receptor (AChR) alpha subunit. We investigated the epitope repertoire of anti-AChR blood CD4+ Th1 cells from 13 myasthenic patients and three healthy controls, using overlapping synthetic peptides screening the alpha subunit sequence and an enzyme-linked immunospot (ELISPOT) assay that detects antigen-induced interferon-gamma secretion of individual Th1 cells. All patients recognized a pool of the alpha subunit peptides. All but one patient recognized numerous peptides. Each patient had an individual pattern of peptide recognition, but most or all patients recognized four sequences (residues 48-67, 101-137, 304-322, and 403-437) that stimulated relatively large numbers of Th1 cells. They include previously identified "immunodominant" sequences recognized by AChR-specific CD4+ T cell lines from myasthenic patients. Peptide 1-14 was also recognized frequently. The controls recognized, with a low precursor frequency, the peptide pool and a few peptides that frequently included the immunodominant sequences described above. The present results demonstrate that Th1 cells are involved in the anti-AChR response in MG and that their epitope repertoire is very complex. This indicates that when MG is clinically evident, the AChR itself is the sensitizing antigen and the target of the autoimmune Th1 cells, although it does not exclude that molecular mimicry between one AChR epitope and a microbial structure may have triggered this autoimmune response. Although the complexity of the Th1 repertoire suggests that development of specific immunosuppressive treatments targeted on epitopes recognized by autoimmune T cells will be difficult, the existence of immunodominant T epitope sequences might facilitate that task.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9191781     DOI: 10.1212/wnl.48.6.1643

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  6 in total

1.  Oral administration of an immunodominant T-cell epitope downregulates Th1/Th2 cytokines and prevents experimental myasthenia gravis.

Authors:  F Baggi; F Andreetta; E Caspani; M Milani; R Longhi; R Mantegazza; F Cornelio; C Antozzi
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

2.  Intrathymic Tfh/B Cells Interaction Leads to Ectopic GCs Formation and Anti-AChR Antibody Production: Central Role in Triggering MG Occurrence.

Authors:  Xiaoyan Zhang; Shasha Liu; Ting Chang; Jiang Xu; Chunmei Zhang; Feng Tian; Yuanjie Sun; Chaojun Song; Wei Yi; Hong Lin; Zhuyi Li; Kun Yang
Journal:  Mol Neurobiol       Date:  2014-11-19       Impact factor: 5.590

3.  Mapping myasthenia gravis-associated T cell epitopes on human acetylcholine receptors in HLA transgenic mice.

Authors:  Huan Yang; Elzbieta Goluszko; Chella David; David K Okita; Bianca Conti-Fine; Teh-sheng Chan; Mathilde A Poussin; Premkumar Christadoss
Journal:  J Clin Invest       Date:  2002-04       Impact factor: 14.808

4.  Prevention of experimental myasthenia gravis by nasal administration of synthetic acetylcholine receptor T epitope sequences.

Authors:  P I Karachunski; N S Ostlie; D K Okita; B M Conti-Fine
Journal:  J Clin Invest       Date:  1997-12-15       Impact factor: 14.808

5.  The role of IFN-gamma Elispot assay in HIV vaccine research.

Authors:  Hendrik Streeck; Nicole Frahm; Bruce D Walker
Journal:  Nat Protoc       Date:  2009       Impact factor: 13.491

6.  Predicting HLA CD4 Immunogenicity in Human Populations.

Authors:  Sandeep Kumar Dhanda; Edita Karosiene; Lindy Edwards; Alba Grifoni; Sinu Paul; Massimo Andreatta; Daniela Weiskopf; John Sidney; Morten Nielsen; Bjoern Peters; Alessandro Sette
Journal:  Front Immunol       Date:  2018-06-14       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.